A Study of Infliximab in the Treatment of Chinese Children With Crohn's Disease
Launched by JOHNSON & JOHNSON (CHINA) INVESTMENT LTD. · Mar 16, 2020
Trial Information
Current as of August 11, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Must have a confirmed diagnosis of Crohn's disease
- • Must sign, and their legal guardians/legally-acceptable representative where applicable must sign, a participation agreement/ICF allowing data collection and source data verification in accordance with local requirements
- • First-time received IFX treatment
- Exclusion Criteria:
- • History of medical contraindications for Infliximab (IFX), example. serious infections, active tuberculosis (TB), lymphoma and other malignancies, moderate to severe heart failure, hypersensitivity to inactive components of the product or to any murine proteins
- • Previous exposure to Infliximab or any other biologics
- • Received an investigational drug (including investigational vaccines) or used an invasive investigational medical device within 90 days before the start of the study or the first data collection time point
- • Currently enrolled in an investigational study
- • Have other Crohn's-like disease that are associated with mono-genetic immune disorders
About Johnson & Johnson (China) Investment Ltd.
Johnson & Johnson (China) Investment Ltd. is a subsidiary of the global healthcare leader Johnson & Johnson, dedicated to advancing health and well-being in China. With a commitment to innovation and excellence, the company engages in the research, development, and commercialization of a wide range of pharmaceutical, medical device, and consumer health products. Leveraging cutting-edge science and a deep understanding of local healthcare needs, Johnson & Johnson (China) Investment Ltd. aims to deliver impactful solutions that enhance patient outcomes and contribute to the overall improvement of health systems across the region.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Shanghai, , China
Shanghai, , China
Hangzhou, , China
Guangzhou, , China
Zhengzhou, , China
Shanghai, , China
Hangzhou, , China
Patients applied
Trial Officials
Johnson & Johnson (China) Investment Ltd. Clinical Trial
Study Director
Johnson & Johnson (China) Investment Ltd.
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials